Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for Characterization...

Xennex Inc. Providing Satoris Inc. with Latest GeneCards(R) Tools for
Characterization of Protein Biomarkers Associated With Neurological Conditions

CAMBRIDGE, Mass., April 20 /PRNewswire/ -- Xennex Inc. (Xennex) announced
today that it is collaborating with Satoris Inc. (Satoris) and has provided
Satoris with access to GeneCards(R) and associated proprietary tools,
including GeneAlaCart and early access to input from the advanced prototype of
GeneCards(R) version 3.0, which is in advanced stages of development. Satoris
is utilizing GeneCards and the related technology for research related to its
identification and characterization of protein biomarkers associated with
neurological disease such as Alzheimer's, Parkinson's, Multiple Sclerosis, and
Diabetic Neuropathy to create new diagnostic tools for earlier, better
healthcare decisions.

"We welcome the opportunity to collaborate with Xennex and utilize the newest
available GeneCards tools in the further characterization of plasma protein
biomarkers we have identified in our studies as being significant in
neurodegenerative disease process," said Cris McReynolds, President & CEO of
Satoris.

Dr. David Warshawsky, President & CEO of Xennex, stated: "We are very pleased
that we can offer Satoris with our most advanced tools and the latest
GeneCards developments to assist in their work. Satoris' work is of great
potential for improved diagnosis and treatment of devastating conditions and
we are delighted that GeneCards is assisting in this important cutting-edge
research."

About GeneCards(R)

GeneCards(R) (http://www.genecards.org) is a searchable, integrated database
of human genes that provides concise genomic, proteomic, transcriptomic,
genetic and functional information on all known and predicted human genes.
Information featured in GeneCards includes orthologies, disease relationships,
mutations and SNPs, gene expression, gene function, pathways, protein-protein
interactions, related drugs & compounds and direct links to cutting-edge
research reagents and tools such as antibodies, recombinant proteins, clones,
expression assays and RNAi reagents. GeneCards was developed over the last 12
years by a world-leading bioinformatics team at the Weizmann Institute of
Science in Israel.

About Xennex

Founded in 2003, Xennex Inc. (http://www.xennexinc.com) is a dynamic privately
held company that is dedicated to providing Biotechnology, Pharmaceutical and
other life sciences companies, as well as organizations dealing with
biotechnology intellectual property, the highest level of services and tools
to enhance their gene-based research. Xennex' products help such organizations
to optimize their efforts to develop innovative medical products and services.

Xennex' customers include many of the world's leading Biotech and
Pharmaceutical companies and organizations dealing with intellectual property,
located in North America, Europe and Japan. Xennex' products are used in
hundreds of commercial and academic organizations by tens of thousands of
users around the globe.

About Satoris

Founded in 2003 and based in Redwood City, California, Satoris, Inc. is a
molecular diagnostics company focused on developing blood-based tests for
Alzheimer's disease. For more information, see http://www.satorisinc.com.

For further information, please contact:

Xennex Inc.
David Warshawsky, Ph.D.
Chief Executive Officer
Tel: +1 617 497 7774
davidw@xennexinc.com

This release was issued through eReleases(TM). For more information, visit
http://www.ereleases.com.

SOURCE Xennex Inc.

David Warshawsky, Ph.D., Chief Executive Officer of Xennex Inc.,
+1-617-497-7774, davidw@xennexinc.com